New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin

PfizerPfizer Consumer Healthcare has announced the launch of Centrum®VitaMints®, a great-tasting and easy-to-take multivitamin that offers consumers the essential nutrients they can enjoy like a mint, from Centrum®, a brand they know and trust.

"Americans want to live well - they want to eat right and exercise often - however they are often short on the time needed to support an active, healthy lifestyle," said Bahar Takhtehchian, lifestyle and wellness expert. "By offering a multivitamin in a flavor many consumers love, Centrum® VitaMints® give consumers an on-the-go option they enjoy like a mint that helps support energy, immunity and metabolism."

Centrum® VitaMints® is a refreshing and complete multivitamin that provides a more enjoyable experience for consumers to get essential nutrients, and joins other Centrum products to form one of the most comprehensive lines of multivitamins on the market.

"Pfizer Consumer Healthcare is committed to bringing a range of exciting new Centrum multivitamin formulas to market that seamlessly fit into Americans' everyday lives, including Centrum® VitaMints®, a surprisingly and refreshing mint tasting multivitamin that breaks through in a category traditionally known for tablets and gummies," said Robert Uccardi, Director for Centrum, Pfizer Consumer Healthcare.

Centrum® VitaMints® in Cool Mint flavor is intended for adults, and includes such key nutrients as Vitamins A, C, D and E, amongst others. Serving size is two minty chewables daily which can be taken with or without food or water. When it comes to any consumer health product, consumers should always read and follow the directions on the product label, including the recommended daily servings.

Available at major retailers nationwide and online, Centrum® VitaMints® is sold in 60- and 120-count bottles.

It is important to note, dietary supplements are not intended to diagnose, treat, cure or prevent any disease but rather help consumers fill daily dietary gaps.

About Centrum®
With over 35 years of nutritional science expertise, Centrum® multivitamins remain the multivitamin chosen for multiple landmark studies on long-term health benefits and continue to be the most-clinically studied, most-preferred and most-doctor and pharmacist recommended multivitamin brand in America. Centrum® is a complete multivitamin that delivers a combination of essential vitamins and minerals that help support overall health and well-being. Centrum® multivitamins support multiple health benefits such as energy, immunity, heart health, bone health, eye and skin health. To see what nutrients are inside Centrum®, and learn more about our product formulations, please visitwww.Centrum.com (link is external).

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Abbott launches new initiative to drive diversity …

Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, ed...

Needle-free COVID-19 vaccine shows promise

A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed...

Cleveland Clinic launches first-of-its kind preven…

Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of ...

Novartis to sell its Roche stake in a bilateral tr…

Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. Vas...